Target intelligence / Profile preview

BLTP3B divergent transcript (BLTP3B-DT)

Target
BLTP3B-DT
Molecular classification
Long non-coding RNA (lncRNA), Divergent transcript, Other
01

Overview

BLTP3B divergent transcript (BLTP3B-DT) is a long non-coding RNA annotated as a divergent transcript from the promoter region of the UHRF1BP1L gene (BLTP3B). Divergent transcription refers to the bidirectional transcribing activity of RNA polymerase II at gene promoters, generating a protein-coding mRNA in one direction and a noncoding RNA in the other. These divergent lncRNAs, such as BLTP3B-DT, may regulate gene expression through mechanisms including modifying chromatin structure, recruiting transcriptional machinery, or creating competitive promoter environments. However, for BLTP3B-DT specifically, no experimentally validated functional studies or therapeutic relevance have been reported. It is classified as a long non-coding RNA belonging to the broad family of divergent transcripts, and does not encode a protein. Current genomic databases list it as a noncoding transcript, and there is no evidence for its involvement in disease, biomarker utility, or drug interactions.

Other names
UHRF1BP1L-DTUHRF1BP1L divergent transcriptBLTP3B-DT
02

Mechanism of action

None reported; for lncRNAs generally, possible mechanisms include recruitment of chromatin modifiers or modulation of transcription factor binding

03

Biological functions

Unknownlikely gene regulation (inferred from the general functions of divergent lncRNAs, such as recruitment of chromatin remodelers or modulation of nearby gene expression)
04

Disease associations

Unknown (no direct disease associations reported)some divergent lncRNAs have roles in cancer, immunity, and development

Beyond the preview

Go deeper on BLTP3B divergent transcript (BLTP3B-DT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BLTP3B divergent transcript (BLTP3B-DT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call